VANCOUVER, B.C. — A class action in British Columbia Supreme Court claims Teva Canada, Sandoz Canada, et al. failed to warn patients prescribed Valsartan (hydrochlorothiazide) for hypertension that the drug was recalled as possibly carcinogenic, possibly because of contamination by its Chinese supplier.
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
EU says member states can use bloc’s funds for ‘safe’ abortion access February 26, 2026 -
-
Veterans urge Second Circuit to lower bar for IVF benefits February 26, 2026 -
EU trade surplus with US hits 5-year low as tariff truce unravels February 26, 2026